Additional file 4: Figure S3. of A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
- Petra Seibold (463199)
- Peter Schmezer (125415)
- Sabine Behrens (395469)
- Kyriaki Michailidou (205130)
- Manjeet Bolla (3412991)
- Qin Wang (109812)
- Dieter Flesch-Janys (89907)
- Heli Nevanlinna (83762)
- Rainer Fagerholm (89888)
- Kristiina Aittomäki (3437822)
- Carl Blomqvist (83761)
- Sara Margolin (146586)
- Arto Mannermaa (89891)
- Vesa Kataja (89896)
- Veli-Matti Kosma (89895)
- Jaana Hartikainen (146589)
- Diether Lambrechts (101772)
- Hans Wildiers (146595)
- Vessela Kristensen (25468)
- Grethe AlnĂŚs (3527723)
- Silje Nord (665045)
- Anne-Lise Borresen-Dale (2697364)
- Maartje Hooning (146690)
- Antoinette Hollestelle (52748)
- Agnes Jager (659189)
- Caroline Seynaeve (95368)
- Jingmei Li (254314)
- Jianjun Liu (28194)
- Keith Humphreys (28187)
- Alison Dunning (10539)
- Valerie Rhenius (3505079)
- Mitul Shah (51821)
- Maria Kabisch (820179)
- Diana Torres (2697346)
- Hans-Ulrich Ulmer (3527681)
- Ute Hamann (89879)
- Joellen Schildkraut (3104691)
- Kristen Purrington (3423128)
- Fergus Couch (89911)
- Per Hall (23544)
- Paul Pharoah (15105)
- Doug Easton (553718)
- Marjanka Schmidt (3437726)
- Jenny Chang-Claude (23562)
- Odilia Popanda (125366)
Publication date
December 2015
DOIAbstract
Meta-analysis across BCAC studies of XRCC1 and breast cancer prognosis. Forest plot of the combined hazard ratios and 95Â % confidence intervals for XRCC1 rs3213356 in the discovery MARIE study and the replication studies in Breast Cancer Association Consortium (BCAC) using fixed effect models, according to treatment, i.e. no chemotherapy (A), any type of chemotherapy (B), and anthracycline-based chemotherapy (C). The combined effects for the BCAC studies were also based on fixed effect models. (DOCX 1077 kb
Add to ORKG